ClinVar Miner

Submissions for variant NM_000303.3(PMM2):c.722G>C (p.Cys241Ser) (rs80338709)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
EGL Genetic Diagnostics,Eurofins Clinical Diagnostics RCV000153745 SCV000232518 pathogenic not provided 2014-01-03 criteria provided, single submitter clinical testing
Center for Pediatric Genomic Medicine,Children's Mercy Hospital and Clinics RCV000153745 SCV000610219 pathogenic not provided 2017-04-25 criteria provided, single submitter clinical testing
Invitae RCV000008156 SCV000633728 pathogenic Congenital disorder of glycosylation, type Ia 2018-12-20 criteria provided, single submitter clinical testing This sequence change replaces cysteine with serine at codon 241 of the PMM2 protein (p.Cys241Ser). The cysteine residue is moderately conserved and there is a moderate physicochemical difference between cysteine and serine. This variant is present in population databases (rs80338709, ExAC 0.06%). This variant is a common cause of mild congenital disorder of glycosylation Ia (CDG-Ia). It has been reported as compound heterozygous in multiple affected individuals with evidence of segregation with disease within families (PMID: 21541725, 25355454, 15844218, 11715002, 11156536). Fibroblasts from individuals carrying this variant show residual PMM2 activities of 5-31% (PMID: 21541725). ClinVar contains an entry for this variant (Variation ID: 7717). Experimental studies have shown that this missense change impairs PMM2 protein function and results in an enzyme with residual activity in vitro (PMID: 11715002, 21541725, 22012410, 26014514). For these reasons, this variant has been classified as Pathogenic.
Integrated Genetics/Laboratory Corporation of America RCV000008156 SCV000696504 pathogenic Congenital disorder of glycosylation, type Ia 2017-06-26 criteria provided, single submitter clinical testing Variant summary: The PMM2 c.722G>C (p.Cys241Ser) variant involves the alteration of a conserved nucleotide. 4/4 in silico tools predict a damaging outcome for this variant (SNPsandGO not captured due to low reliability index). This variant was found in 9/120396 control chromosomes at a frequency of 0.0000748, which does not exceed the estimated maximal expected allele frequency of a pathogenic PMM2 variant (0.0055902). The variant has been reported in numerous CDG1A patients and has been associated with a mild phenotype. Patient fibroblasts (which also carry a second pathogenic variant) show ~30% residual enzyme activity, and functional studies using expression systems also show <30% residual enzyme activity. Multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic. Taken together, this variant is classified as pathogenic.
Ambry Genetics RCV000623621 SCV000741806 pathogenic Inborn genetic diseases 2016-09-16 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: POSITIVE: Relevant Alteration(s) Detected
Fulgent Genetics,Fulgent Genetics RCV000008156 SCV000894097 pathogenic Congenital disorder of glycosylation, type Ia 2018-10-31 criteria provided, single submitter clinical testing
OMIM RCV000008156 SCV000028361 pathogenic Congenital disorder of glycosylation, type Ia 2001-02-01 no assertion criteria provided literature only
GeneReviews RCV000008156 SCV000040591 pathologic Congenital disorder of glycosylation, type Ia 2011-04-21 no assertion criteria provided curation Converted during submission to Pathogenic.
Counsyl RCV000008156 SCV000487108 pathogenic Congenital disorder of glycosylation, type Ia 2016-10-12 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.